Instructions Write a four-page paper identifying the regulatory agency or policy that would have an effect on the core measure improvement plan on Sepsis Management   The paper, as well as the referen

*** ****** ** ********** ******** ** ****** **************** ** ***** *** **** daunting conditions that ****** ********** ******* ********* ** ** a **************** sickness that ******* from *** ****** ********* ** * ****** ********* ********* ** tissue ****** ***** failure and death ********* ********** *** **** essential ** ****** ***** *** preventing ********* ********* ***** ********** ******** have ****** a *********** **** ** *********** *** ********* standards *** the quality and ****** ** care *** ****** ********* *** **** of *** ******* *** ******** and ******** ******** *** ***** ****** core measures in ********* *** ********** ** sepsis **** *** ** understanding sepsis ********** ******* **** my *********** in ********** ***** such ******** **** ***** *********** I **** ******* ** *** ******** challenges and successes **** **** been ************* ** *** ******* *** Medicare *** ******** ******** ************ for ******** *** ******** Services is an ****** ** *** ****** ****** Health *** ***** ******** ********** **** ****** ******** critical medical ********** ******** **** Medicare ******** *** *** ***** ********** ****** ********* Program ************** ******* ** the ******* *** ****** ** **** which *** ********* ********* ** *** **** ** CMS *** *** *** enforced using ******* ******** and incentives *** of the *********** *********** ** *** ******** *** ************** ** ****** **** ******** specifically ******** ** ******* ***** ************** *** ********** ** ****** ****** Sepsis *** ****** Shock (van ***** ***** *** ***** These *** detailed ** *** 1; ** ****** an organized ****** *** managing ****** specifying *** **** ********* **** must ** ********* ****** ******** time frames SEP-1 ******** *** ****** ****** *************** ** *** **** ** ****** ***** ****** facilities ensuring conformance with ************** ********* In particular *** **** ** ******* ******* outcomes ***** ******** mortality rates ** making ********** ********* liable *** ********** quality ****** **** through timely *** ********* ************* ***** ** Fig * ***** ***** an example ** *** ****** *** Medicare *** Medicaid ******** *********** ** *** Centers *** ******** ***** ******** ******** ***** data ********* Sepsis **** ******* ********** ********* *** **** ** **** ********** *** ****** **** ******* ***** to set ** a higher degree ** ********** *** adherence to evidence-based ********** *** ******** sepsis clinically ***** ********* a ****** of care processes that **** ** ********* ****** ******** time ****** for ******** diagnosed **** ****** ***** ****** **** ******* *********** of ******* to define *** degree of ****** at the **** ********* ** ********* ***** ******** ****** ********** *********** ** * *** to identify *** causative ******** ****** *** *********** ************** ** broad-spectrum antibiotics ** control ********* followed ** ******** ***** ************* ** ****** *********** of ***** pressure ***** ********* among others **** comprehensive ********* *** *** ********* management ** ****** ** facilitated through *** SEP-1 ******* that ********* *** **************** of ********** ********* ******* ****** reporting *** ********* ********** ***** ** ** ***** The accountability ******** ****** and appropriate **** *** sepsis ***** providers ********* ******* ******** *** ******** mortality ***** ******* ** ****** ** shown ** Fig * ********** ** *** ****** Core MeasureImpact ** ***** ** ****** ManagementImplementing ***** core measures ** ****** has ************* ******* sepsis ********* in ********** facilities ***** ***** * ***** management **** **** *** ******** ****** ** ****** ********* *** is **** ******* ** *** ***** ************** ** *** condition *** *** ****** ********** ********** **** **** *** **** ******* ****** ****** ********* rates **** ************ **** reduced ****** patients' outcomes **** favorableInitial ******* Level ***************** ***** Management ****** ***** ** SEP-1 ** ******* in ****** ********** *** *** of the ************ for ********* ***** ** the **** ** perform an ******* ***** ******* ***** **** ****** *** ***** * ***** ** diagnosing *** ****** **** ********* lactate ***** reflects tissue ************* and is associated **** *** rising ******** ** ****** ********* ***** identification *** lead ** early ********** ***** ******** actions **** ********** ***** replacement ** *********** use ** necessary *********** et ** 2021) **** this ******** measure CMS will ********* **** providers *********** devote ******** emphasis ** the timely ************** ** severe ****** ********* *** ******* of ******* and ******** ********* The ***** ********* **** **** *** ***** ************ ********* ** ***** *** possibility *** 'saleable' ******* outcomes **** *** ********* *** ** ****** ****** ** septic ***** ***************** ***** ******** ****** Administering ****************** large part of ***** ** the ************** to obtain ***** ******** before ********** administration ** is ********* ** identify *** *********** ******** and ************* ****** antibiotic ******* **** ****** and appropriate ********** ************** is ******* ** ****** **** ***** delays *** ********** **** **** ******** ***** ***** ** this ******* *** ******** ********* ** **** best ******** ******* ********** a patient's ******* ** getting *** infection ******* and ******** ******* ************* (Martínez ** al ***** It **** therefore ****** ****** *** ********* treatment to ******* ******* ******** *** ****** ********* **** ************ Administration of ************** ************* all *** measures SEP-1 **** * premium ** ****** ************** ********* **** ***** hours ** ********* ** sepsis *** one **** *** diagnosis ** septic ***** Quick ********* *** ********* ** ******* the **** ** *** ********* and prevent ******* *********** *** **** **** ******** ** *** measure that it *********** the process (Venkatesh et ** 2022) So far as ********* are concerned ********** *** is ****** ********* *** focus ** ****** ******** *** ************* ******** ******* outcomes reducing the ******** ** infections and ******** ********* ***** *** measure ********** *** ******** a prompt ********** ******** is ** *********** sepsis ****************** ********** ** ********** ******** a ****** ****** I **** **** ******** involved ** *** ************** and ******** of **** ******** for sepsis at ** *********** *** ******* ********* * ***** was ***** ********** with *** ***** bundle ** **** *** I ********** ** education *** training ****** on *** ***** *********** ** ****** and ****** ************ *** *** clinical ***** It *** ** ******* ** simulation practice *** the ***** protocols ** a ********** environment *** feedback *** ********* for *************** Logistical ChallengesAnother ********** ********* ** process improvement *** getting a ***** ******* ****** ********** placement ******* of this * *********** **** *** ********** ** facilitate *** ******* and **** blood ******** 'stat' ** patients **** ********* ****** ** ******** good ************* *** ************ between the ******** and laboratory ***** *** regular interdisciplinary *************** *** **** **************** ** *** ********* concerning ************ *** SEP-1 ******** *** ********** a ****** response **** *** ********** *** ****** **** ** ****** *** ***** ****** ************* ***** **** ** ******** ** ******** ********* ** ****** alert ************* *** ensured *** ***** ****** *** ******************* ******************* data-driven *************** ******* *** * ******* ** ***** I ******** that *************** ** ***** ** **** integration ** ********* ******* care ****** **** conducted ** ******* ********* *** there **** feedback sessions ********* staff ******** ********** with ************ ******** *** ***** **** by looking ** *** data and ******* ** **** *** staff I ***** *** ********** improvement *** maintain **** ********* of **** *** ****** ********************* **** **** **** ********** ******** ********** *** *** have ****** ** ******* ******* ******** ** sepsis ********** cannot be ************** ************ ****** **** measures ***** *** visibly improved ***** *********** *** ********* ** sepsis **** ********* ******* ******** ****** *** a ****** ** engage ** leadership * have **** ***** ********** ******** bear significant ****** ** healthcare ********* and ******* **** ********** ******* **** *********** **** ***** ***** ******* ********* collaboration *** *********** *************** ** **** ********** ************* ****** *** ********** ********* ** *** management ** ****** **** by **** ********** ******* ** compliance *** best ******** will **** ******** ****** quality *** ****** ** ********** ********* care delivered *** ******** **** ***************************** * * ************** E P *************** * C & Ferrer * ****** ** ******** ** ********** treatment ** patients **** ****** ******* ** ******** ******* 12(3) *********** https://doiorg/1021037/jtd20200147Rhee C ******* * Cosgrove * * **** E L ***** * * Kalil * * ******* D N Masur * ******** * J ******* D * Strich * * ******* D * & ******* M ****** ********** ******** ******* of ******* position paper: *********** ********* to *** ******** ****** sepsis and ****** ***** early ********** ****** ******* ****** ******* ******* Clinical Infectious Diseases ************************************ ***** * * ***** *** * * ****** ** Centers for ******** *** Medicaid ******** Quality ******** reflect ****************** ********* Value ** ****** ********************************************* B ********** * Mason D ***** * ****** * ****** P ***** * **** * Redpath * Gibbons * ****** E ***** **** M (2022) ****** ** 1-hour and ****** ****** time ******* ** ******* outcomes *** ************* **** * before *** after cohort ***** The ****** ******** ****** - Western ******* 18 ****** ************************************************* * Klompas * & **** * (2021) What ** *** ******* of ********* ******* ****** in patients with ****** *** ****** ****** ******** ** Respiratory *** ******** **** ******** ****** 650–661 ************************************